Alethea V Cope - JoVE Visualize

Showing results (1-10 of 7) with videos related to

Pageof 1

Sort By:

Frontiers in Microbiology|June 2, 2017

Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody TitreVictoria M W Gould, James N Francis, Katie J Anderson, et al.

Plos One|January 28, 2014

Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimenPaul F McKay, Alethea V Cope, Jamie F S Mann, et al.

Proceedings. Biological Sciences|July 11, 2006

Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesisRoland R Regoes, E Frances Bowen, Alethea V Cope, et al.

Frontiers in Immunology|January 11, 2020

The Safety and Immunogenicity of GTU<sup>®</sup>MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ARTG Haidari, Suzanne Day, M Wood, et al.

Plos One|May 10, 2016

Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre StudyCatherine A Cosgrove, Charles J Lacey, Alethea V Cope, et al.

Frontiers in Immunology|March 10, 2017

A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.

Frontiers in Immunology|May 21, 2019

Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and SequenceYuka Nadai, Kathrin Held, Sarah Joseph, et al.

Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:

Pageof 1

Frontiers in Microbiology|June 2, 2017

Nasal IgA Provides Protection against Human Influenza Challenge in Volunteers with Low Serum Influenza Antibody TitreVictoria M W Gould, James N Francis, Katie J Anderson, et al.

Plos One|January 28, 2014

Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimenPaul F McKay, Alethea V Cope, Jamie F S Mann, et al.

Proceedings. Biological Sciences|July 11, 2006

Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesisRoland R Regoes, E Frances Bowen, Alethea V Cope, et al.

Frontiers in Immunology|January 11, 2020

The Safety and Immunogenicity of GTU<sup>®</sup>MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ARTG Haidari, Suzanne Day, M Wood, et al.

Plos One|May 10, 2016

Comparative Immunogenicity of HIV-1 gp140 Vaccine Delivered by Parenteral, and Mucosal Routes in Female Volunteers; MUCOVAC2, A Randomized Two Centre StudyCatherine A Cosgrove, Charles J Lacey, Alethea V Cope, et al.

Frontiers in Immunology|March 10, 2017

A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization RegimesSarah Joseph, Killian Quinn, Aldona Greenwood, et al.

Frontiers in Immunology|May 21, 2019

Envelope-Specific Recognition Patterns of HIV Vaccine-Induced IgG Antibodies Are Linked to Immunogen Structure and SequenceYuka Nadai, Kathrin Held, Sarah Joseph, et al.

Pageof 1